IL142107A0 - Use of specific hybrid promoters for controlling tissue expression - Google Patents

Use of specific hybrid promoters for controlling tissue expression

Info

Publication number
IL142107A0
IL142107A0 IL14210799A IL14210799A IL142107A0 IL 142107 A0 IL142107 A0 IL 142107A0 IL 14210799 A IL14210799 A IL 14210799A IL 14210799 A IL14210799 A IL 14210799A IL 142107 A0 IL142107 A0 IL 142107A0
Authority
IL
Israel
Prior art keywords
hybrid promoters
tissue expression
specific hybrid
controlling tissue
controlling
Prior art date
Application number
IL14210799A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9812000A external-priority patent/FR2783839B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL142107A0 publication Critical patent/IL142107A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14210799A 1998-09-25 1999-09-23 Use of specific hybrid promoters for controlling tissue expression IL142107A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9812000A FR2783839B1 (fr) 1998-09-25 1998-09-25 Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire
US12329899P 1999-03-04 1999-03-04
PCT/FR1999/002265 WO2000018908A1 (fr) 1998-09-25 1999-09-23 Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire

Publications (1)

Publication Number Publication Date
IL142107A0 true IL142107A0 (en) 2002-03-10

Family

ID=26234566

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14210799A IL142107A0 (en) 1998-09-25 1999-09-23 Use of specific hybrid promoters for controlling tissue expression

Country Status (9)

Country Link
EP (1) EP1115857A1 (fr)
JP (1) JP2002525109A (fr)
KR (1) KR20010075338A (fr)
CN (1) CN1326506A (fr)
AU (1) AU775717B2 (fr)
CA (1) CA2343922A1 (fr)
HU (1) HUP0105230A3 (fr)
IL (1) IL142107A0 (fr)
WO (1) WO2000018908A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004502426A (ja) 2000-07-05 2004-01-29 トランジェーヌ、ソシエテ、アノニム 平滑筋の発現を制御するキメラプロモーター
EP1310561A1 (fr) * 2001-11-09 2003-05-14 Transgene S.A. Promoteurs chimeriques permettant de commander l'expression dans des cellules de muscles squelettiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266490A (en) * 1991-03-28 1993-11-30 Regeneron Pharmaceuticals, Inc. Mammalian expression vector
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
DK0787200T3 (da) * 1994-10-28 2005-08-15 Univ Pennsylvania Forbedret adenovirus og fremgangsmåder til anvendelse heraf
CA2274314C (fr) * 1996-12-02 2007-03-13 Genemedicine, Inc. Systeme d'expression du facteur de croissance insulinoide i (igf-i) et ses methodes d'utilisation

Also Published As

Publication number Publication date
AU775717B2 (en) 2004-08-12
WO2000018908A1 (fr) 2000-04-06
EP1115857A1 (fr) 2001-07-18
JP2002525109A (ja) 2002-08-13
HUP0105230A2 (hu) 2002-04-29
AU5632499A (en) 2000-04-17
HUP0105230A3 (en) 2003-10-28
CN1326506A (zh) 2001-12-12
CA2343922A1 (fr) 2000-04-06
KR20010075338A (ko) 2001-08-09

Similar Documents

Publication Publication Date Title
AU6359898A (en) Apparatus for controlled thermal treatment of tissue
AU693826B2 (en) Instrument for the penetration of body tissue
AU3673499A (en) Hydrogel for the therapeutic treatment of aneurysms
ZA984939B (en) Absorbent surgical drape
IL136311A0 (en) Soft absorbent tissue products
HUP9902770A3 (en) Modulators of tissue regeneration
AU2111500A (en) Bone tissue regenerating composition
AU6242298A (en) Methods for promoting healing of corneal resurfacing wounds
AU7582398A (en) Composition for treating skin conditions
AU1673100A (en) Simulated body tissue
AU3891299A (en) Combination therapy for treatment of depression
SG103270A1 (en) Applicator for tampons
AU7592998A (en) Modulators of tissue regeneration
PL348107A1 (en) Therapy for improving cognition
IL122976A0 (en) Control of cd44 gene expression for therapeutic use
IL127496A0 (en) The use of MMP inhibitors for the treatment of ocular angiogenesis
SG90108A1 (en) Control of multiple equivalent functional units for power reduction
AU1588099A (en) Hybrid tissues for tissue engineering
EP1041887A4 (fr) Agents de lutte biologique destines a agir sur les maladies des racines
AU5487699A (en) Adhesive compositions for the hard tissues of the human body
AU3145795A (en) Fibrin-cell suspension for construction of new tissue
AU2603301A (en) 6-keto prostaglandin F1alpha and analogs for treating dry eye
AU7755398A (en) Method for reducing body weight
AU1878201A (en) Composition for the treatment of damaged tissue
HUP0105230A3 (en) Use of specific hybrid promoters for controlling tissue expression